Torrance Clinical Research   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Lomita CA United States (2011)

Organization Overview

First Clinical Trial
2011
NCT01188928
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

DBA Torrance Clinical Research | Torrance Clinical Research Institute Inc., Lomita, CA 90717

Active Ingredients

Drugs in Phase 3 Trials (2)

betamethasone (celestone) (1 trial)

calcipotriene (dovonex) (1 trial)

Drugs in Phase 2 Trials (2)

favipiravir (1 trial)

ingenol mebutate (picato) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Influenza, Human (Phase 2)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4